To prospectively evaluate the distribution of PSMA-targeted PET-avid lesions in prostate cancer (PCa) patients with biochemical recurrence in a Chinese cohort. The relationships between PSA levels, disease-free time after prostatectomy, and 68Ga-PSMA-11 PET/computed tomography (CT) findings were investigated. Inclusion criteria included histopathologically proven prostate adenocarcinoma, two consecutive PSA levels > 0.20 ng/mL, and negative CT of the abdomen and pelvis or magnetic resonance imaging of the pelvis and whole-body bone scan. Exclusion criteria were non-prostate malignancy within 3 years and persistent PSA after radical prostatectomy. Patients with findings of recurrent disease on re-staging conventional imaging were excluded, as were patients previously treated with systemic therapy and/or salvage therapy. 51 patients were enrolled in this study. 34/51 (66.7%) patients had at least one site of 68Ga-PSMA-11 uptake consistent with PCa. 23.5% of patients had recurrence in the prostate bed, 27.4% had pelvic lymph nodes, 15.7% had extrapelvic lymph node metastases, and 17.6% had bone metastases. For patients with lymph node involvement/metastasis, bone metastasis, and patients with both, their median serum PSA levels were 1.83 ng/mL, 4.03 ng/mL, and 2.54 ng/mL, respectively. They were diagnosed with recurrence with a median of 2.06 years, 1.15 years, and 2.54 years after radical prostatectomy, respectively. In this study of Chinese men with biochemical recurrence, added value for the detection of lesions compatible with sites of PCa was found with 68Ga-PSMA-11 PET/CT over conventional imaging. The observed patterns of disease spread may have implications for understanding the biology of early prostate cancer metastasis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
Van Der Toom EE, Axelrod HD, Jean J, et al. Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol. 2019;16(1):7–22.
Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517–23.
Albisinni S, Artigas C, Aoun F, et al. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 2017;120:197–203.
Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58(10):1545–52.
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA–PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226.
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40.
Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [Ga-68] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.
Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68 Ga] Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18 F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–6.
Meredith G, Wong D, Yaxley J, et al. The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118:49–55.
Afaq A, Alahmed S, Chen SH, et al. Impact of 68Ga-prostate-specific membrane antigen PET/CT on prostate cancer management. J Nucl Med. 2018;59(1):89–92.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.
Byrne K, Eade T, Kneebone A, et al. Delineating sites of failure following post-prostatectomy radiation treatment using Ga-68-PSMA-PET. Radiother Oncol. 2018;126:244–8.
Schmuck S, Nordlohne S, von Klot CA, et al. Comparison of standard and delayed imaging to improve the detection rate of [Ga-68]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:960–8.
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117–36.
De Visschere PJ, Standaert C, Fütterer JJ, et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol. 2019;2(1):47–76.
Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Willliams J, Calais J. Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.230318.
Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44(1):92–101.
Gupta M, Choudhury PS, Hazarika D, Rawal S. A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience. World J Nucl Med. 2017;16(3):186–91.
Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286–94.
Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786–93.
Rowe SP, Campbell SP, Mana-Ay M, et al. Prospective evaluation of PSMA-targeted 18F-DCFPyL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer. J Nucl Med. 2019:jnumed-119.
Schmuck S, Nordlohne S, von Klot CA, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga] PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):960–8.
Schmuck S, Mamach M, Wilke F, et al. Multiple time-point 68Ga-PSMA I&T PET/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging. Clin Nucl Med. 2017;42(6):e286–93.
Afshar-Oromieh A, Hetzheim H, Kübler W, et al. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43(9):1611–20.
Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1.
Mehra R, Kumar-Sinha C, Shankar S, et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011;17(12):3924–32.
Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15(2):677–83.
Chalfin HJ, Glavaris SA, Malihi PD, et al. Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms. J Urol. 2018;199(6):1494–501.
Horn T, Kronke M, Rauscher I, et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;76(4):517–23.
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol. 2018;73(4):485.
LD is supported by Shanghai Natural Science Foundation exploration Project (17ZR1447400). MX is supported by National Natural Science Foundation of China (81701725), Shanghai “Rising Stars of Medical Talent” Youth Development Program (SHDC2012105). SRA is supported by the Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation. WX is supported by Program of Shanghai Subject Chief Scientist (19XD1402300) and Program for Outstanding Medical Academic Leader (2019LJ11). KJP is supported by NCI grants U54CA143803, CA163124, CA093900, and CA143055, and the Prostate Cancer Foundation. SPR is supported by the Prostate Cancer Foundation.
LD is supported by Shanghai Natural Science Foundation exploration project (17ZR1447400). MX is supported by National Natural Science Foundation of China (81701725), Shanghai “Rising Stars of Medical Talent” Youth Development Program (SHDC2012105). SRA is supported by the Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation. WX is supported by Program of Shanghai Subject Chief Scientist (19XD1402300) and Program for Outstanding Medical Academic Leader (2019LJ11). KJP is supported by NCI grants U54CA143803, CA163124, CA093900, and CA143055, and the Prostate Cancer Foundation. SPR is supported by the Prostate Cancer Foundation.
Conflicts of interest
The authors report no relevant conflicts of interest.
Consent to participate
Written, informed consent was obtained from all patients.
Consent for publication
Patients signed informed consent regarding publishing their data and photographs.
This prospective study was approved by the Committee for Ethics of Renji Hospital, Shanghai Jiao Tong University School of Medicine.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Dong, L., Zhu, Y., Xin, M. et al. Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. Med Oncol 37, 89 (2020). https://doi.org/10.1007/s12032-020-01412-7
- Prostate-specific membrane antigen
- Prostate cancer
- Biochemical recurrence